Mimedx (MDXG) Operating Expenses (2011 - 2026)
Mimedx recorded quarterly Operating Expenses of $57.4 million in Q1 2026, up 245.59% quarter-over-quarter from $16.6 million in Q4 2025, and down 9.36% year-over-year from $63.3 million in Q1 2025.
Mimedx's Operating Expenses history runs 16 years deep, the most recent figure standing at $57.4 million for Q1 2026.
- In Q1 2026, Operating Expenses fell 9.36% year-over-year to $57.4 million; the TTM figure through Mar 2026 stood at $166.3 million (up 8.39% YoY), while the FY2025 annual figure was $71.6 million, up 15.75% from the prior year.
- Operating Expenses came in at $57.4 million for Q1 2026 at Mimedx, up from $16.6 million in the prior quarter.
- In the past five years, Operating Expenses ranged from a high of $72.7 million in Q3 2025 to a low of $13.5 million in Q1 2024.
- A 5-year average of $46.0 million and a median of $55.9 million in 2023 frame the typical range for Operating Expenses.
- Across the five-year window, Operating Expenses tumbled 75.79% in 2024 and surged 369.11% in 2025, its largest moves.
- Mimedx's Operating Expenses stood at $45.1 million in 2022, then rose by 25.89% to $56.8 million in 2023, then plunged by 70.11% to $17.0 million in 2024, then slipped by 2.2% to $16.6 million in 2025, then surged by 245.59% to $57.4 million in 2026.
- According to Business Quant data, Operating Expenses over the past three periods registered $57.4 million, $16.6 million, and $72.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 2.97 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 4.33 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -138.30 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 15.76 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.85 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -3.82 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 2.96 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 898.54 Mn |
| 10 | Mimedx | 530.69 Mn | 370.92 Mn | 41.62 Mn | 57.37 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 57.37 Mn |
| Dec 31, 2025 | 16.60 Mn |
| Sep 30, 2025 | 72.70 Mn |
| Jun 30, 2025 | 19.59 Mn |
| Mar 31, 2025 | 63.30 Mn |
| Dec 31, 2024 | 16.97 Mn |
| Sep 30, 2024 | 56.43 Mn |
| Jun 30, 2024 | 16.69 Mn |
| Mar 31, 2024 | 13.49 Mn |
| Dec 31, 2023 | 56.78 Mn |
| Sep 30, 2023 | 55.85 Mn |
| Jun 30, 2023 | 58.88 Mn |
| Mar 31, 2023 | 55.73 Mn |
| Dec 31, 2022 | 45.11 Mn |
| Sep 30, 2022 | 59.43 Mn |
| Jun 30, 2022 | 61.31 Mn |
| Mar 31, 2022 | 55.53 Mn |
| Dec 31, 2021 | 46.72 Mn |
| Sep 30, 2021 | 50.66 Mn |
| Jun 30, 2021 | 57.66 Mn |
| Mar 31, 2021 | 49.74 Mn |
| Dec 31, 2020 | 52.14 Mn |
| Sep 30, 2020 | 51.42 Mn |
| Jun 30, 2020 | 39.59 Mn |
| Mar 31, 2020 | 49.59 Mn |
| Dec 31, 2019 | 48.16 Mn |
| Sep 30, 2019 | 53.95 Mn |
| Jun 30, 2019 | 53.47 Mn |
| Mar 31, 2019 | 53.76 Mn |
| Dec 31, 2018 | 70.84 Mn |
| Sep 30, 2018 | 62.70 Mn |
| Jun 30, 2018 | 71.30 Mn |
| Mar 31, 2018 | 69.46 Mn |
| Dec 31, 2017 | 55.09 Mn |
| Sep 30, 2017 | 65.71 Mn |
| Jun 30, 2017 | 60.06 Mn |
| Mar 31, 2017 | 57.15 Mn |
| Dec 31, 2016 | 47.57 Mn |
| Sep 30, 2016 | 51.10 Mn |
| Jun 30, 2016 | 45.94 Mn |
| Mar 31, 2016 | 43.14 Mn |
| Dec 31, 2015 | 38.87 Mn |
| Sep 30, 2015 | 37.09 Mn |
| Jun 30, 2015 | 34.71 Mn |
| Mar 31, 2015 | 31.14 Mn |
| Dec 31, 2014 | 31.09 Mn |
| Sep 30, 2014 | 26.21 Mn |
| Jun 30, 2014 | 22.99 Mn |
| Mar 31, 2014 | 17.24 Mn |
| Dec 31, 2013 | 15.66 Mn |
| Sep 30, 2013 | 14.00 Mn |
| Jun 30, 2013 | 11.79 Mn |
| Mar 31, 2013 | 9.62 Mn |
| Dec 31, 2012 | 9.28 Mn |
| Sep 30, 2012 | 6.60 Mn |
| Jun 30, 2012 | 3.55 Mn |
| Mar 31, 2012 | 3.04 Mn |
| Dec 31, 2011 | 2.81 Mn |
| Sep 30, 2011 | 2.92 Mn |
| Jun 30, 2011 | 3.50 Mn |
| Mar 31, 2011 | 3.59 Mn |